{"id":34944,"date":"2024-02-06T17:15:20","date_gmt":"2024-02-06T15:15:20","guid":{"rendered":"https:\/\/irbstage.vetim.ch\/?p=34944"},"modified":"2024-02-06T17:15:20","modified_gmt":"2024-02-06T15:15:20","slug":"targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future","status":"publish","type":"post","link":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/","title":{"rendered":"Targeting licensed immune cells in cancer therapy: a new frontier for the future"},"content":{"rendered":"<p><strong>IRB Special Seminar<\/strong><\/p>\n<p><strong>Prof. Domenico Mavilio<br \/>\n<\/strong>Principal Investigator, Head, Unit of Clinical and Experimental Immunology, Department of Medical Biotechnologies and Translational Medicine, Medical School of Milan University, Humanitas Research Hospital, Rozzano, Milan (IT)<\/p>\n<p>Thursday, February 29, 2024<br \/>\nat 12:00 pm<br \/>\nBios+ Seminar Room<\/p>\n<p>Contact: Prof. Greta Guarda<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IRB Special Seminar Prof. Domenico Mavilio Principal Investigator, Head, Unit of Clinical and Experimental Immunology, Department of Medical Biotechnologies and Translational Medicine, Medical School of Milan University, Humanitas Research Hospital, Rozzano, Milan (IT) Thursday, February 29, 2024 at 12:00 pm Bios+ Seminar Room Contact: Prof. Greta Guarda<\/p>\n","protected":false},"author":136,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-34944","post","type-post","status-publish","format-standard","hentry","category-events"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI\" \/>\n<meta property=\"og:description\" content=\"IRB Special Seminar Prof. Domenico Mavilio Principal Investigator, Head, Unit of Clinical and Experimental Immunology, Department of Medical Biotechnologies and Translational Medicine, Medical School of Milan University, Humanitas Research Hospital, Rozzano, Milan (IT) Thursday, February 29, 2024 at 12:00 pm Bios+ Seminar Room Contact: Prof. Greta Guarda\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\" \/>\n<meta property=\"og:site_name\" content=\"IRB USI\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-06T15:15:20+00:00\" \/>\n<meta name=\"author\" content=\"Andrea Nava\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrea Nava\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/\"},\"author\":{\"name\":\"Andrea Nava\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#\\\/schema\\\/person\\\/01bacbaaa75ea23cfc275a8fb0e0ab94\"},\"headline\":\"Targeting licensed immune cells in cancer therapy: a new frontier for the future\",\"datePublished\":\"2024-02-06T15:15:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/\"},\"wordCount\":57,\"publisher\":{\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#organization\"},\"articleSection\":[\"Events\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/\",\"url\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/\",\"name\":\"Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#website\"},\"datePublished\":\"2024-02-06T15:15:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/events\\\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Events\",\"item\":\"https:\\\/\\\/irbstage.vetim.ch\\\/.\\\/events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Targeting licensed immune cells in cancer therapy: a new frontier for the future\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/\",\"name\":\"IRB USI\",\"description\":\"Institute for Research in Biomedicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#organization\",\"name\":\"IRB USI\",\"url\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/irbstage.vetim.ch\\\/images\\\/IRB-Usi.svg\",\"contentUrl\":\"https:\\\/\\\/irbstage.vetim.ch\\\/images\\\/IRB-Usi.svg\",\"width\":98,\"height\":43,\"caption\":\"IRB USI\"},\"image\":{\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/irbstage.vetim.ch\\\/it\\\/#\\\/schema\\\/person\\\/01bacbaaa75ea23cfc275a8fb0e0ab94\",\"name\":\"Andrea Nava\",\"sameAs\":[\"https:\\\/\\\/irbstage.vetim.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/","og_locale":"it_IT","og_type":"article","og_title":"Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI","og_description":"IRB Special Seminar Prof. Domenico Mavilio Principal Investigator, Head, Unit of Clinical and Experimental Immunology, Department of Medical Biotechnologies and Translational Medicine, Medical School of Milan University, Humanitas Research Hospital, Rozzano, Milan (IT) Thursday, February 29, 2024 at 12:00 pm Bios+ Seminar Room Contact: Prof. Greta Guarda","og_url":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/","og_site_name":"IRB USI","article_published_time":"2024-02-06T15:15:20+00:00","author":"Andrea Nava","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Andrea Nava","Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/#article","isPartOf":{"@id":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/"},"author":{"name":"Andrea Nava","@id":"https:\/\/irbstage.vetim.ch\/it\/#\/schema\/person\/01bacbaaa75ea23cfc275a8fb0e0ab94"},"headline":"Targeting licensed immune cells in cancer therapy: a new frontier for the future","datePublished":"2024-02-06T15:15:20+00:00","mainEntityOfPage":{"@id":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/"},"wordCount":57,"publisher":{"@id":"https:\/\/irbstage.vetim.ch\/it\/#organization"},"articleSection":["Events"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/","url":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/","name":"Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI","isPartOf":{"@id":"https:\/\/irbstage.vetim.ch\/it\/#website"},"datePublished":"2024-02-06T15:15:20+00:00","breadcrumb":{"@id":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irbstage.vetim.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irbstage.vetim.ch\/it\/"},{"@type":"ListItem","position":2,"name":"Events","item":"https:\/\/irbstage.vetim.ch\/.\/events\/"},{"@type":"ListItem","position":3,"name":"Targeting licensed immune cells in cancer therapy: a new frontier for the future"}]},{"@type":"WebSite","@id":"https:\/\/irbstage.vetim.ch\/it\/#website","url":"https:\/\/irbstage.vetim.ch\/it\/","name":"IRB USI","description":"Institute for Research in Biomedicine","publisher":{"@id":"https:\/\/irbstage.vetim.ch\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irbstage.vetim.ch\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/irbstage.vetim.ch\/it\/#organization","name":"IRB USI","url":"https:\/\/irbstage.vetim.ch\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/irbstage.vetim.ch\/it\/#\/schema\/logo\/image\/","url":"https:\/\/irbstage.vetim.ch\/images\/IRB-Usi.svg","contentUrl":"https:\/\/irbstage.vetim.ch\/images\/IRB-Usi.svg","width":98,"height":43,"caption":"IRB USI"},"image":{"@id":"https:\/\/irbstage.vetim.ch\/it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/irbstage.vetim.ch\/it\/#\/schema\/person\/01bacbaaa75ea23cfc275a8fb0e0ab94","name":"Andrea Nava","sameAs":["https:\/\/irbstage.vetim.ch"]}]}},"_links":{"self":[{"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/posts\/34944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/users\/136"}],"replies":[{"embeddable":true,"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/comments?post=34944"}],"version-history":[{"count":1,"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/posts\/34944\/revisions"}],"predecessor-version":[{"id":34945,"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/posts\/34944\/revisions\/34945"}],"wp:attachment":[{"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/media?parent=34944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/categories?post=34944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irbstage.vetim.ch\/it\/wp-json\/wp\/v2\/tags?post=34944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}